Clinical trials: Genome
Genome Instability, Genetic Predisposition to Disease
Mutational Oncology in Clinical Practice
The study of biological profiling is of fundamental importance in the diagnosis and treatment of many diseases, particularly oncological ones, and for this reason, the integration of molecular characterization into clinical…
- Conditions
- Genome Instability, Genetic Predisposition to Disease, Gene Rearrangement
- Trial name
- FPG-500 (NCT06020625)
- Testing
- Diagnostic Test
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Solid Tumors
Feasibility Clinical Study of Targeted and Genome-Wide Sequencing
This research is being done to find out what types of gene mutations are present in people with cancer. This study is designed to help researchers and doctors understand more about cancer.
- Trial name
- NCT01345513
- Testing
- Sample Collection for Genome-Wide Sequencing
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Genetic Disease
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
The goal of this clinical trial is to test a new method for newborn screening using whole genome sequencing, called BeginNGS. Parents will be approached to provide informed consent to enroll their newborns in prenatal, postnatal…
- Trial name
- BeginNGS (NCT06306521)
- Testing
- BeginNGS Test
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rady Pediatric Genomics & Systems Medicine Institute
Kidney Transplantation
TOlerance MOlecular and Genome-wide Studies With Renal Allograft Recipient Material
TOMOGRAM is a European multicentric, prospective, experimental, controlled study that aims to increase our understanding of the causative mechanisms of operational tolerance in kidney transplantation through the achievement of…
- Trial name
- TOMOGRAM (NCT05124444)
- Testing
- High throughput DNA and RNA sequencing
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Université Libre de Bruxelles
Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
Background: Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and it has grown more prevalent in the United States.
- Conditions
- Carcinoma, Hepatocellular, Liver Cirrhosis, Alcoholic, Hepatitis, Alcoholic, Hepatitis, Chronic
- Trial name
- NCT00913757
- Where
- 2 sites in United States
- Volunteers
- 1,871 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes
iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes
This open-label, randomized, parallel group phase II study will investigate the efficacy of computational biology-informed treatment vs.
- Trial name
- NCT03446638
- Testing
- FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction
- Where
- United States
- Sponsor
- University of Florida
Rare Diseases
Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas
The purpose of this study is to provide advanced genetic testing and virtual consultations for seriously ill newborns in hospitals in Texas with fewer resources, especially along the Texas-Mexico border.
- Trial name
- MAGNET (NCT07102966)
- Testing
- Rapid whole genome sequencing
- Where
- United States
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
DiGeorge Syndrome, 22q11.2 Deletion Syndrome
Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
22q11.2 deletion syndrome is a genetic disorder that can cause heart defects, facial abnormalities, and developmental and learning disabilities. The severity of the disorder can vary widely among people.
- Trial name
- NCT00556530
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Albert Einstein College of Medicine
Colon Adenocarcinoma, High-Frequency Microsatellite Instability
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other…
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma
- Trial name
- NCT03436563
- Testing
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received…
- Conditions
- Advanced Triple Negative Breast Cancer, Breast Cancer Metastatic, Breast Cancer
- Trial name
- NCT07299409
- Testing
- Sacituzumab Govitecan (SG)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nathalie Levasseur
Cardiovascular Phenotype, Metabolic Phenotype
Implications of Maternal 45,X Mosaicism as a Secondary Genomic Finding Following Cell-Free DNA Sequencing During Pregnancy: A Deep Phenotype Study
Background: Mosaicism is a condition in which cells within the same person have a different genetic makeup. Sometimes, a type of mosaicism called 45,X may not be discovered in a woman until she undergoes routine tests during…
- Conditions
- Cardiovascular Phenotype, Metabolic Phenotype, Hypertensive Disease, Psychological Phenotype
- Trial name
- NCT05548881
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Insulin Sensitivity, Aging
Implication of Metabolic and Genomic Modifications in Elderly Subjects
An increase of longevity and of the number of men and women older than 60 years old is observed in most industrialized countries.
- Trial name
- COMPALICLAMP (NCT00951392)
- Testing
- euglycemic hyperinsulinemic clamp, muscle biopsy, indirect calorimetry
- Where
- France
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Positron-Emission Tomography, Carcinoma, Hepatocellular
Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma
The aim of this study is to make up for this gap by performing a dynamic scan of 18F-FDG PET/CT on newly diagnosed patients with liver cancer. The lesions and/or metastases are performed for biopsy.
- Trial name
- NCT03636607
- Testing
- PET/CT dynamic scan
- Where
- China
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Ischemia-reperfusion (IR) Injury
Clinical and Genomic Responses to Open Heart Surgery
This study will be the first large scale randomized study of remote ischemic preconditioning (RIPC) ever performed and will define the role of this novel therapy as a clinical tool.
- Trial name
- NCT00650507
- Testing
- Remote ischemic preconditioning (RIPC)
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- The Hospital for Sick Children
Multiple Sclerosis
Genes and Environment in Multiple Sclerosis
The purpose of the research study is to identify the genetic, environmental and immune profiles that may increase a person's risk of developing multiple sclerosis (MS).
- Trial name
- GEMS (NCT01353547)
- Where
- 5 sites in United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Diabetes Mellitus
Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical Diabetes
The main objective of the study is to assess the contribution of whole genome sequencing (WGS) coupled with a multidisciplinary conciliation meeting (MCM) on diagnosis of atypical forms of diabetes compared to an in-silico…
- Trial name
- GLUCOGEN (NCT06570278)
- Testing
- WGS coupled with MCM
- Where
- 26 sites in France
- Volunteers
- 1,020 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Neurodegenerative Diseases
Big Data and Genomic Imaging for the Development of Biomarkers and Nanovector Drugs Innovative for Diagnosis and Therapy of Inflammatory Processes in Dementia
The correlation between data obtained by "imaging" in patients with neurodegenerative diseases characterized by inflammation and the presence in the peripheral blood of the same patients "biopsies liquid biopsies" of specific…
- Trial name
- BigImAGING (NCT05761535)
- Testing
- Magnetic Resonance (MR) and positron emission tomograph (PET) imaging analyses
- Where
- Italy
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- IRCCS SYNLAB SDN
Venous Thromboembolism (VTE), NSCLC (Advanced Non-small Cell Lung Cancer)
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
Multicenter, prospective observational study (15 Oncologic Centers, in Italy). The purpose of the study is to assess the thromboembolic potential in patients with oncogene-addicted and wild-type NSCLC.
- Trial name
- NCT07288632
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University Of Perugia
Early-Stage Breast Cancer, Neoadjuvant Therapy
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
The COGNITION diagnostic platform elucidates the biomarker profile of neoadjuvant chemotherapy-resistant residual bulk tumors in high risk early breast cancer patients.
- Trial name
- COGNITION (NCT05906407)
- Testing
- Genomic Profiling / Sequencing
- Where
- 12 sites in Germany
- Volunteers
- 2,000 people
- Sponsor
- German Cancer Research Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer
This phase II trial studies how well genetic testing works in predicting tumor response in patients with stage I-III HER2 negative invasive breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT01334021
- Testing
- Biopsy, Conventional Surgery, Genetic Testing
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.